Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
Express Scripts
Moodys
Harvard Business School

Last Updated: December 7, 2022

Dalteparin sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for dalteparin sodium and what is the scope of freedom to operate?

Dalteparin sodium is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for dalteparin sodium. One supplier is listed for this compound.

Summary for dalteparin sodium
Recent Clinical Trials for dalteparin sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Xijing HospitalPhase 2/Phase 3
PharmaDiall Ltd.Phase 2
Federal University of São PauloPhase 4

See all dalteparin sodium clinical trials

Pharmacology for dalteparin sodium
Medical Subject Heading (MeSH) Categories for dalteparin sodium

US Patents and Regulatory Information for dalteparin sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-007 Apr 4, 2002 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-010 May 1, 2007 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-011 May 1, 2007 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-012 Mar 15, 2022 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for dalteparin sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-001 Dec 22, 1994 See Plans and Pricing See Plans and Pricing
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-004 Jan 30, 1998 See Plans and Pricing See Plans and Pricing
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-003 Mar 18, 1996 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.